Modality
siRNA
MOA
JAK1i
Target
JAK1
Pathway
RNA Splicing
ObesityALL
Development Pipeline
Preclinical
~Nov 2019
→ ~Feb 2021
Phase 1
May 2021
→ Jan 2028
Phase 1Current
NCT08928139
2,200 pts·ALL
2021-05→2028-01·Not yet recruiting
2,200 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-071.8y awayPh2 Data· ALL
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Not yet…
Catalysts
Ph2 Data
2028-01-07 · 1.8y away
ALL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08928139 | Phase 1/2 | ALL | Not yet recr... | 2200 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα |